AVA6103 added to the US National Cancer Institute's NCI Thesaurus on 26 October 2026, receiving its own standardised biomedical terminology entry (C229108).
https://t.co/HdtPN5ThEp
#AVCT
Ongoing patent activity around #AVCT's Affimer immunotherapy platform - divisional patent application filed in May and published this morning in Japan.
Serum Half-Life Prolonging PD-L1 Inhibiting Polypeptide.
https://t.co/Vt5BGnc4Nb
@tom_the_bomb__ "Any interest from big pharmas, either licensing or partnering?"
"I can't disclose too much... but I would say that we're having a number of very interesting combinations, all of the pharmas out there have their own toxic drugs."
Edited slightly for character limit.
Another new paper from Roche - next-gen FAP-targeted combo therapies for difficult tumours like pancreatic, with activation only in the TME to avoid systemic immune/drug activation.
#AVCT may be of interest Roche 😁
https://t.co/yRujScOfnb
@doraandash No worries - mostly just Google and LinkedIn, searching for most recent posts containing Avacta related keywords, or the pages most recently indexed by Google 👍🏼 LinkedIn is good for finding industry conferences and events